Study suggests new way to prevent vision loss in diabetics and premature babies

March 22, 2017
Secretogranin III induces the formation of blood vessels in the eye of a diabetic mouse (left) but has no effect on the eye of a healthy rodent (right). Credit: LeBlanc et al., 2017

Researchers at Bascom Palmer Eye Institute, part of the University of Miami Miller School of Medicine, have identified a new molecule that induces the formation of abnormal blood vessels in the eyes of diabetic mice. The study, "Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy," which will be published March 22 in The Journal of Experimental Medicine, suggests that inhibiting this molecule may prevent similarly aberrant blood vessels from damaging the vision of not only diabetics, but also premature infants.

Changes in the vasculature of diabetes patients can cause long-term complications such as , which affects around 93 million people worldwide. Many of these patients suffer a dramatic loss of vision as the supplying the retina become leaky and new, are formed to replace them. A molecule called vascular endothelial growth factor (VEGF) regulates and leakiness, and two VEGF inhibitors, ranibizumab (Lucentis) and aflibercept (Eylea), have been approved to treat retinal vascular leakage, though they are only successful in about a third of patients.

The growth of abnormal new vessels also causes retinopathy of prematurity (ROP), the most common cause of vision loss in children that affects up to 16,000 premature infants per year in the US. VEGF inhibitors are not approved for use in these patients because VEGF is crucial for vascular development in newborn children.

Study lead-author Wei Li, Ph.D., research associate professor, and his colleagues at Bascom Palmer developed a technique called "comparative ligandomics" to identify additional molecules that regulate the behavior of blood vessels in diabetic mice. The approach allows the researchers to compare the signaling molecules that selectively bind to the surface of retinal in diabetic but not healthy animals.

"It is estimated that between one third and one half of all marketed drugs act by binding to cell surface signaling molecules or their receptors," says Li. "Our ligandomics approach can be applied to any type of cell or disease to efficiently identify signaling molecules with pathogenic roles and therapeutic potential."

Using this technique, Li and colleagues discovered that a protein called secretogranin III (Scg3) efficiently binds to the surface of retinal blood vessel cells in diabetic, but not healthy, mice. Though Scg3 promotes the secretion of hormones and other signaling factors, it wasn't thought to have a signaling function itself. Nevertheless, the researchers found that Scg3 increased vascular leakage, and, when administered to mice, it stimulated blood vessel growth in diabetic, but not healthy, animals.

VEGF, in contrast, stimulates blood vessel growth in both diabetic and healthy mice. Li and colleagues think that Scg3 binds to a distinct cell surface receptor that is specifically up-regulated in diabetes.

Treating with Scg3-neutralizing antibodies dramatically reduced the leakiness of their . Moreover, the antibodies significantly inhibited the growth of new blood vessels in mice with oxygen-induced retinopathy, a well-established animal model of human ROP.

Though the researchers still need to confirm the role of Scg3 in humans, inhibiting this protein could be an effective treatment for both diabetic retinopathy and ROP, especially as it appears to have no role in normal vascular development. "Scg3 inhibitors may offer advantages such as disease selectivity, high efficacy, and minimal side effects," Li says. "Because they target a distinct signaling pathway, anti-Scg3 therapies could be used in combination with, or as an alternative to, VEGF inhibitors."

Explore further: Growth factor shown to protect the retina in early stage diabetes

More information: LeBlanc et al. 2017. J. Exp. Med. jem.rupress.org/cgi/doi/10.1084/jem.20161802

Related Stories

Growth factor shown to protect the retina in early stage diabetes

February 2, 2017
Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have shown that a slight increase in transforming growth factor beta (TGF-β), which is present in preclinical animal models with diabetic ...

Study suggests new way of preventing diabetes-associated blindness

May 25, 2015
Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, ...

Powerful anti-inflammatory molecule may block vision loss in diabetic retinopathy

January 3, 2017
A more powerful version of an anti-inflammatory molecule already circulating in our blood may help protect our vision in the face of diabetes.

Blood vessel research offers insights into new treatments for eye diseases

May 27, 2014
(Medical Xpress)—Leukaemia drugs could help to improve treatments for blindness caused by abnormal blood vessel growth in the eye, finds new UCL research. The study, published in the Journal of Experimental Medicine, raises ...

Poor anti-VEGF responses linked to genetic variation in immune regulation

December 5, 2016
Anti-VEGF therapies are commonly used to stabilize deteriorating vision in patients with wet age-related macular degeneration (wet AMD). Vascular endothelial growth factor, or VEGF, is a signaling molecule that helps maintain ...

Cancer drug shows promise for treating stroke

April 2, 2015
A University of Victoria neuroscientist has discovered that a cancer drug may improve recovery rates for diabetic patients who have suffered a stroke.

Recommended for you

Newly published research provides new insight into how diabetes leads to retinopathy

December 7, 2017
An international team of scientists led by Professor Ingrid Fleming of Goethe University, Frankfurt, Germany, and including Professor Bruce Hammock of the University of California, Davis, provides new insight into the mechanism ...

Researchers use breakthrough technology to understand eclipse eye damage

December 7, 2017
In a first-of-its-kind study, Mount Sinai researchers are using adaptive optics (AO) to analyze retinal eye damage from the August solar eclipse on a cellular level. The research could help doctors develop a deeper understanding ...

Combating eye injuries with a reversible superglue seal

December 6, 2017
When a soldier sustains a traumatic eye injury on the battlefield, any delay in treatment may lead to permanent vision loss. With medical facilities potentially far away and no existing tools to prevent deterioration, medics ...

Trigger for most common form of vision loss discovered

November 27, 2017
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the ...

Scientists engineer drug delivery device that treats glaucoma directly inside the eye

November 23, 2017
Glaucoma, which affects over 60 million people worldwide, can seem easy to treat: medicated eye drops can be used to ease the buildup of fluid in the eye that underlies the condition. If glaucoma is caught early, eye drops ...

Research reveals biological mechanism of a leading cause of childhood blindness

November 16, 2017
Scientists at the Virginia Tech Carilion Research Institute (VTCRI) have revealed the pathology of cells and structures stricken by optic nerve hypoplasia, a leading cause of childhood blindness in developed nations.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.